A phase 3 trial (DREAMseq) in previously untreated BRAF‐mutated melanoma compared niv/ipi as first line and then switched to dab/tra at disease progression with dab/tra as first line and then switched to niv/ipi at disease progression.65 The gene discussed is BRAF; the disease is melanoma.